Advertisement

Evofem Biosciences, Inc. EVFM

Set alert

Price alert · EVFM

All alert types
0.01 USD 0.00 0.00%

At close · Oct 30

0.006 Day range 0.0063
0.001 52-week range 0.014
YTD
-40.00%
1 year
-50.00%
Open
0.0063
Prev close
0.006
Mkt cap
795.18K
Vol
14.92K
Avg vol
169.79K
EPS
-0.11
P/E
0.00
Div yield
0.00%
More statistics
Low
0.006
High
0.0063
Forward P/E
-0.48
Beta
-1.68
Short ratio
0.19
Inst. own
9.67%
Dividend
0.00
Ex-div date
50-d avg
0.74126
200-d avg
3.61
1y target
11.05

6M chart

Chart tools
Interval

Signals (76)
NameDateAgo
MACD: Sell SignalOct 29, 20262 days ago
MACD: Buy SignalOct 27, 20264 days ago
MACD: Sell SignalOct 14, 20262 weeks ago
SMA: BearishOct 13, 20262 weeks ago
SMA: BearishOct 13, 20262 weeks ago
MACD: Buy SignalOct 8, 20263 weeks ago
SMA: BullishOct 7, 20263 weeks ago
SMA: BullishOct 7, 20263 weeks ago
SMA: BearishOct 5, 20263 weeks ago
SMA: BearishOct 5, 20263 weeks ago
SMA: BullishOct 2, 20264 weeks ago
SMA: BullishOct 2, 20264 weeks ago
SMA: BearishSep 30, 20261 month ago
SMA: BearishSep 30, 20261 month ago
MACD: Sell SignalSep 30, 20261 month ago
SMA: BullishSep 29, 20261 month ago
SMA: BullishSep 29, 20261 month ago
MACD: Buy SignalSep 29, 20261 month ago
SMA: BearishSep 28, 20261 month ago
SMA: BearishSep 28, 20261 month ago
MACD: Sell SignalSep 28, 20261 month ago
SMA: BullishSep 21, 20261 month ago
SMA: BullishSep 21, 20261 month ago
MACD: Buy SignalSep 21, 20261 month ago
SMA: BearishSep 18, 20261 month ago
SMA: BearishSep 18, 20261 month ago
MACD: Sell SignalSep 18, 20261 month ago
SMA: BullishSep 16, 20261 month ago
SMA: BullishSep 16, 20261 month ago
MACD: Buy SignalSep 16, 20261 month ago
SMA: BearishSep 15, 20261 month ago
SMA: BearishSep 15, 20261 month ago
MACD: Sell SignalSep 15, 20261 month ago
MACD: Buy SignalSep 11, 20261 month ago
SMA: BullishSep 10, 20261 month ago
SMA: BullishSep 10, 20261 month ago
SMA: BearishSep 8, 20261 month ago
MACD: Sell SignalSep 8, 20261 month ago
MACD: Buy SignalAug 27, 20262 months ago
SMA: BullishAug 26, 20262 months ago
SMA: BearishAug 24, 20262 months ago
MACD: Sell SignalAug 24, 20262 months ago
MACD: Buy SignalAug 14, 20262 months ago
MACD: Sell SignalAug 12, 20262 months ago
MACD: Buy SignalAug 11, 20262 months ago
MACD: Sell SignalAug 10, 20262 months ago
SMA: BearishAug 7, 20262 months ago
SMA: BearishAug 7, 20262 months ago
SMA: BullishAug 6, 20262 months ago
SMA: BullishAug 6, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago
SMA: BearishJul 30, 20263 months ago
SMA: BearishJul 13, 20263 months ago
MACD: Sell SignalJul 13, 20263 months ago
SMA: BullishJul 6, 20263 months ago
MACD: Buy SignalJul 6, 20263 months ago
SMA: BearishJul 2, 20264 months ago
MACD: Sell SignalJul 2, 20264 months ago
SMA: BullishJul 1, 20264 months ago
MACD: Buy SignalJul 1, 20264 months ago
MACD: Sell SignalJun 30, 20264 months ago
SMA: BearishJun 26, 20264 months ago
SMA: BullishJun 24, 20264 months ago
SMA: BearishJun 23, 20264 months ago
SMA: BullishJun 17, 20264 months ago
SMA: BullishJun 17, 20264 months ago
SMA: BearishJun 16, 20264 months ago
SMA: BullishJun 12, 20264 months ago
SMA: BearishJun 11, 20264 months ago
SMA: BearishJun 5, 20264 months ago
SMA: BullishJun 4, 20264 months ago
SMA: BullishJun 3, 20265 months ago
MACD: Buy SignalMay 21, 20265 months ago
MACD: Sell SignalMay 19, 20265 months ago
MACD: Buy SignalMay 14, 20265 months ago
RSI: OversoldMay 5, 20265 months ago

Key statistics

Market cap
27.34M
Enterprise value
137.13M
Trailing P/E
0.00
Forward P/E
-0.48
PEG ratio
0.00
Price / sales
1.76
Price / book
0.00
EPS (TTM)
-19.01
Beta
-1.68
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
15.57M
Revenue growth
224.90%
Free cash flow
68.23M
Total cash
19.89M
Total debt
125.74M
Return on equity
0.00%
Shares outstanding
85.46M
Short % of float
24.67%
50-day average
0.74126
200-day average
3.61

Analyst view

Consensus: buy

Buy
Price target (mean) 11.05 +184066.7% upside
Target (low)
0.75
Target (mean)
11.05
Target (high)
45.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.44.

Earnings history

Financials — quick view

All financials
EVFM Revenue — quarterly 5.81M
2019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-09-302022-12-312023-03-31
EVFM Net income — quarterly -2.35M
2019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-09-302022-12-312023-03-31
EVFM EPS — quarterly -1.85
2019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-09-302022-12-312023-03-31

Earnings

EVFM recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.02——
Aug 14, 2024Jun 1, 20240.000.00——
May 15, 2024Mar 1, 20240.00-0.16——
Mar 27, 2024Dec 1, 20230.00-0.44——
Nov 14, 2023Sep 1, 20230.000.10——
Aug 14, 2023Jun 1, 20230.00-5.43——

Upgrades / downgrades

EVFM analyst upgrades and downgrades
DateFirmActionFromTo
Aug 15, 2022HC Wainwright & Co.main—Buy
Jul 15, 2022Morgan Stanleymain—Underweight
Jun 2, 2022Laidlaw & Co.init—Buy
May 25, 2022Piper Sandlermain—Overweight
May 11, 2022Morgan Stanleymain—Underweight
May 10, 2022Morgan Stanleymain—Underweight

About Evofem Biosciences, Inc.

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
evofem.com

News

Your note

Sign in to keep a note on EVFM — it syncs with the Stock Master app.

Insider holders

EVFM insider holders
InsiderRelationLatest transactionDateShares held
BARRANS RUSSELLOfficerPurchaseJun 10, 2021468,831
CULWELL KELLYOfficerStock Award(Grant)Feb 2, 2021315,451
FILE JUSTIN JChief Financial OfficerStock Award(Grant)Feb 17, 2022810,982
FITZPATRICK ALEXANDER A.General CounselStock Award(Grant)Feb 17, 2022516,422
HALL WILLIAM WALMSLEYDirectorPurchaseJun 14, 20205,000
INVESCO, LTD.Beneficial Owner of more than 10% of a Class of SecurityPurchaseJun 4, 20200

Institution ownership

EVFM institution ownership
Holder% heldSharesValueReported
Baker Brothers Advisors, LLC3.13%2,583,616826.50KJun 29, 2022
Alyeska Investment Group, L.p.2.37%1,950,607624.00KJun 29, 2022
Vanguard Group, Inc. (The)1.58%1,304,514417.31KJun 29, 2022
Citigroup Inc.0.89%736,406235.58KJun 29, 2022
Blackrock Inc.0.28%234,22574.93KJun 29, 2022
Citadel Advisors Llc0.25%210,12267.22KJun 29, 2022

Fund ownership

EVFM fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund0.14%260,67983.39KMar 30, 2022
Vanguard Extended Market Index Fund0.08%154,40449.39KMar 30, 2022
Fidelity Extended Market Index Fund0.07%59,26518.96KJun 29, 2022
Fidelity Total Market Index Fund0.02%14,3584.59KJun 29, 2022
Vanguard Institutional Index-Inst Total Stock Market Ind0.01%8,7912.81KJun 29, 2022
Fidelity Series Total Market Index Fund0.01%8,8312.83KJun 29, 2022
Advertisement